It is the 5th of june, 2019 in Hamburg, Germany. Evotec SE (Frankfurt stock exchance: EVT MDAX/TecDAX, ISIN: DE0005664809) has announced that its strategic partnership with Celgene Corporation has been grown to include a new type of cell that triggered a payment of $9m to Evotec.
The two companies started the collaboration in December 2016 in order to find disease-modifying treatments for a plethora of neurodegenerative diseases. Ever since, the companies have had many achievements including the advancement of a programme into lead optimization as well as the inclusion of addition cell lines and as of now, a new type of cell. The current drugs only offer a short term management of symptoms while there persists a huge need for therapeutic modalities that decrease disease progression in the field of neurodegenerative diseases. The partnership is in pursuit of an innovative approach to the development and discovery of novel medicine by the leveraging of Evotec’s one of a kind human iPSC tech platform, which happens to be among the biggest and most complex platforms in the industry.
As per Dr Cord Dohrmann, the Chief Scientific officer of Evotec, “Patients experiencing neurodegenerative ailments today have restricted treatment alternatives, most of which just help the administration of indications however don’t address the reason for their ailment. With our iPSC stage and Celgene’s mastery, we feel certain to give doctors extra treatment alternatives later on and to convey sickness changing medications to patients.”